Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AVXL 
Anavex Life Sciences Corp (AVXL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: AVXL (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $34.33
1 Year Target Price $34.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.63% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 771.33M USD | Price to earnings Ratio - | 1Y Target Price 34.33 |
Price to earnings Ratio - | 1Y Target Price 34.33 | ||
Volume (30-day avg) 3 | Beta 0.83 | 52 Weeks Range 5.22 - 14.44 | Updated Date 10/17/2025 |
52 Weeks Range 5.22 - 14.44 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.41% | Return on Equity (TTM) -43.64% |
Valuation
Trailing PE - | Forward PE 3.85 | Enterprise Value 683046704 | Price to Sales(TTM) - |
Enterprise Value 683046704 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.54 | Shares Outstanding 85893834 | Shares Floating 83005224 |
Shares Outstanding 85893834 | Shares Floating 83005224 | ||
Percent Insiders 3.36 | Percent Institutions 38.53 |
Upturn AI SWOT
Anavex Life Sciences Corp
Company Overview
History and Background
Anavex Life Sciences Corp. (AVXL) is a biopharmaceutical company founded in 2004. It focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system diseases.
Core Business Areas
- Drug Development: Developing novel drug candidates targeting sigma-1 receptor agonists for neurological disorders.
Leadership and Structure
Christopher U Missling, PhD, is the President and CEO. The company operates with a typical biopharmaceutical structure with departments for research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- ANAVEX2-73 (blarcamesine): ANAVEX2-73 is an oral drug candidate currently in clinical trials for Alzheimer's disease, Rett syndrome, and Parkinson's disease dementia. Market share data is speculative at this stage of development, as it is not yet approved. Competitors in Alzheimer's include Biogen (ADUHELM), Eisai (LEQEMBI), and Eli Lilly (donanemab). Competitors in Rett syndrome include Acadia Pharmaceuticals (DAYBUE).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory scrutiny. The neurological disorder market is large and growing, driven by an aging population and increased awareness of these conditions.
Positioning
Anavex is a clinical-stage biopharmaceutical company focusing on precision medicine for neurological disorders. Its competitive advantage lies in its novel sigma-1 receptor agonist platform and potentially disease-modifying approach.
Total Addressable Market (TAM)
The global market for Alzheimer's disease therapeutics is projected to reach billions of dollars. Anavex, if successful, aims to capture a significant portion of this market. The same applies to Parkinson's Disease and Rett Syndrome.
Upturn SWOT Analysis
Strengths
- Novel drug platform (sigma-1 receptor)
- Potential disease-modifying approach
- Experienced management team
- Multiple clinical trials underway
Weaknesses
- High R&D costs
- Reliance on clinical trial success
- Limited commercial infrastructure
- History of volatility
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Breakthrough Therapy Designation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ACAD
- ESAI
Competitive Landscape
Anavex competes with larger, more established pharmaceutical companies. Its advantage lies in its novel drug platform, but it faces challenges related to funding and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by stock price volatility driven by clinical trial announcements and regulatory milestones.
Future Projections: Future growth is dependent on the success of its clinical trials and potential commercialization of its drug candidates. Analyst estimates vary widely depending on trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for ANAVEX2-73 in Alzheimer's disease, Rett syndrome and Parkinson's disease dementia. And also announcing some other studies.
Summary
Anavex Life Sciences is a clinical-stage biopharmaceutical company with a novel drug platform targeting neurological disorders. Its success hinges on the outcome of ongoing clinical trials for ANAVEX2-73. The company faces competition from established players and regulatory hurdles, but positive trial results could lead to significant stock price appreciation. Anavex's financial performance is closely tied to its clinical development pipeline and ability to secure funding. The company needs to be strategic about its growth and maintain strong shareholder confidence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data for competitors is based on estimations and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anavex Life Sciences Corp
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-08-02 | President, CEO, Secretary & Director Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 42 | Website https://www.anavex.com |
Full time employees 42 | Website https://www.anavex.com | ||
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.